All News

Want to increase cash flow and profits? And create more wealth in the process? There are 3 powerful tools to accomplish that.

Shifting Medicare Part B drugs into Part D may lead to higher costs for Medicare patients with rheumatoid arthritis, according to a new analysis.

Top news of the day from across the health care landscape.

A combination of next generation broadly neutralizing antibodies might be able to achieve long-term viral suppression of HIV without the need for a daily antiretroviral pill, according to recently published research.

Top news of the week from Specialty Pharmacy Times.

Mylan announced Thursday it has launched Medroxyprogesterone Acetate (MPA) Injectable Suspension USP, 150 mg/mL Single-Dose Vial in the United States for the prevention of pregnancy.

This digital technology allows patients to have meaningful conversations with pharmacists from their homes.

The investigational therapy olaparib (Lynparza, AstraZeneca and Merck) has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of pancreatic cancer, according to an AstraZeneca press release.

Provider-centric stigma reduction interventions can help reduce stigmatizing behaviors towards patients with HIV and potentially improve care, according to a new systematic review from the CDC.

Clinical trial demonstrates adoptive T-cell therapy may be successful in treating progressive multifocal leukoencephalopathy.

California’s tobacco control programs have lowered lung cancer deaths 33% faster than the rest of the United States.

Report analyzes HIV-related stigma among health care providers and the potential impact on quality of patient care.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Broadly neutralizing antibodies have one key advantage over antiretroviral therapy: they have a longer half-life and thus don’t require the daily, lifelong dosing regimen currently required of ART users.

Once on preventive therapy, these neuroscience specialist pharmacists will offer coaching for members to achieve optimal medication adherence, and to help members avoid migraine triggers.

Survey participants reported need for better education on how brain atrophy affects multiple sclerosis progression and cognitive loss.

Olaparib (Lynparza, AstraZeneca and Merck), which is being investigated for the treatment of prostate cancer, receives its fourth orphan drug designation from the FDA.

Officials with the FDA have approved talazoparib (Talzenna, Pfizer) for the treatment of HER2-negative locally advanced or metastatic breast cancer with germline BRCA (gBRCA) mutations.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Officials with the Centers for Medicare & Medicaid Services this week proposed requiring drug manufacturers to include prices in direct-to-consumer television advertisements for prescription drugs.

Recent preclinical and population evidence shows cannabis modulates inflammatory and fibrotic processes in the liver, which is promising for treating the symptoms of hepatitis C virus.

Ed Cohen, PharmD, who is Executive Vice President of Pharmacy Advocacy for Pharmacy Times, discusses tips for pharmacists who get questions from patients on the shingles vaccine.

The cannabidiol company and DNA tester will co-market CBD products.

A pair of pivotal Phase 3 placebo-controlled trials that evaluated dupilumab (Dupixent, Sanofi and Regeneron) for adults with inadequately-controlled chronic rhinosinusitis with nasal polyps met all primary and secondary endpoints.

Pharmacy technicians across the country are being honored today in recognition of National Pharmacy Technician Day.

Talazoparib, a poly ADP-ribose polymerase (PARP) inhibitor, is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer who are selected for the therapy based on an FDA-approved companion diagnostic.

Talazoparib is indicated for patients with known deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.

Low-dose aspirin users may have a lower risk of developing ovarian cancer and hepatocellular carcinoma (HCC), according to 2 new studies published in JAMA Oncology.